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ABSTRACT
Reactive arthritis (ReA) with the classic triad of arthritis, conjunctivitis and urethritis, previously termed Reiter’s syndrome, is a systemic 
illness, usually induced by genitourinary or gastrointestinal infections. However, it can be a rare complication of intravesical Bacillus 
Calmette-Guérin instillation (iBCG), a therapy prepared from attenuated strains of Mycobacterium bovis, a common and effective treatment 
for carcinoma in situ of the bladder (CisB). We report a case of a patient with CisB who developed ReA after iBCG. The symptoms resolved 
completely with corticosteroids. iBCG was stopped with no recurrence of carcinoma within 2 years.
LEARNING POINTS
• ReA is an aseptic arthritis, usually triggered by genitourinary or gastrointestinal infections, generally in individuals positive for HLA-B27.
• Septic arthritis and microcrystalline arthritis can mimic ReA and they must be ruled out with arthrocentesis. 
• ReA may be considered as a complication in patients under iBCG. 
KEYWORDS
Reactive arthritis, intravesical Bacillus Calmette-Guérin, carcinoma in situ of the bladder
CASE DESCRIPTION 
A 69-year-old man presented with fever; bilateral, asymmetric and painful arthritis of interphalangeal, tibiotarsal and knee joints, with great 
functional disability and no relief with opioids; bilateral conjunctivitis and scrotum and glans redness, suggestive of urethritis. No recent 
gastrointestinal symptoms were reported. He had a pacemaker and a history of endovascular abdominal aortic aneurysm repair, a coronary 
stent medicated with acetylsalicylic acid, C4-C5 arthroplasty, recurrent gout medicated daily with allopurinol and colchicine and carcinoma 
in situ of the bladder (CisB) under intravesical Bacillus Calmette-Guérin instillation (iBCG). The fifth iBCG was carried out five days before 
the beginning of symptoms. 
Laboratory tests showed high serum uric acid (10.8 mg/dl) and high levels of inflammation (sedimentation rate 100 mm/h, C-reactive protein 
42.2 mg/dl), while PSA was slightly increased (4.71 mg/dl) and urinalysis was normal. 
The patient was maintained on colchicine and antibiotic therapy (AB) was started with ceftriaxone later altered to piperacillin/tazobactam 
and vancomycin due to persistence of fever, no clinical improvement and increased C-reactive protein. 
Diagnostic arthrocentesis was performed. The synovial fluid had normal levels of uric acid and no microcrystals. Cell count was not possible 
but the Gram stain was negative for bacteria and Ziehl-Neelsen staining did not reveal acid-fast bacilli. Microcrystalline arthritis was 
excluded and septic arthritis was less probable, especially after negative cultures for joint fluid (bacteria, mycobacteria and fungi).
With no improvement of arthritis, prednisolone was started with some pain relief and no fever 24 hours later. Inflammatory tests were 
normal 1 week later. 
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Blood and urine cultures (bacteria, mycobacteria and fungi), HIV, hepatitis B and C virus and DNA of Mycobacterium tuberculosis bacilli in 
blood were negative, as were serology tests for Shigella, Mycoplasma, pneumococcus, Campylobacter, Salmonella, parvovirus, Chlamydia and 
Yersinia. HLA-B27 was positive but other immunological tests (antinuclear antibodies, complement levels and rheumatoid factor) were 
normal. 
Due to the presence of medical devices, AB was maintained during the aetiological investigation. Transoesophageal echocardiography was 
performed to exclude endocarditis as well as thoracic-abdominal-pelvic CT, which excluded infectious foci.
The patient was under physical rehabilitation, and despite slow clinical improvement, corticosteroids were progressively reduced with 
complete resolution of arthritis 1 year later. iBCG was not restarted without evidence of CisB during 2 years of follow-up. 
DISCUSSION
Reactive arthritis (ReA) is an autoimmune condition that classically develops 4 weeks after genitourinary infections, especially with 
Chlamydia trachomatis, or gastrointestinal infections by Shigella, Salmonella and Campylobacter. These microorganism triggers can reach the 
joints, although they are not found at sites of arthritis[1].
The diagnosis is based on medical history and clinical examination, with a high index of suspicion when the triad of asymmetric arthritis 
involving large joints in a lower extremity, noninfectious urethritis and conjunctivitis is present.
Despite no specific laboratory or radiological test that can confirm the diagnosis, joint fluid analysis is imperative in order to rule out septic 
and/or microcrystalline arthritis. With aseptic joint fluid, the diagnosis of ReA was more evident. HLA-B27 is usually positive but it is not 
a diagnostic tool. However, it may be helpful for supporting the diagnosis in patients with joint-restricted symptoms and to evaluate the 
severity and chronicity of arthritis [2].
After the negative results for the most common causes of ReA, iBCG as the cause was strongly supported by medical history.
iBCG can cause mild arthralgias but ReA is a very rare, severe adverse effect (incidence of 0.5–1%)[2]. The number (mean of 5.8) and the 
time between the instillation and the onset of symptoms (median 5.0)[2] are not correlated with the severity and prognosis of disease[3]. Two 
clinical patterns have been identified and associated with other musculoskeletal complaints (enthesitis, tendinitis, bursitis and dactylitis). 
The most common form is a symmetric or asymmetric polyarthritis, involving either small-large and upper-lower joints and the less common 
form, an asymmetric mono-oligoarthritis affecting the large joints of lower limbs. Urethritis and conjunctivitis may occur weeks before the 
arthritis [3].
Therapeutic strategies are not well established but include discontinuation of iBCG since a worsening of the arthritis was reported in 83.3% 
of cases that continued the treatment[2] and therapy for symptomatic relief. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most 
widely used and the first-line monotherapy. Corticosteroids have been proposed, especially in cases of NSAID failure, but they also give a 
favourable outcome without recurrence and generally cause a shorter course of arthritis[2]. We preferred corticosteroids because of the 
patient’s history of coronary artery disease. Most cases achieve resolution of symptoms within 6 months[2] but rarely they may progress to 
chronic disease. In these cases, methotrexate can be indicated and it was considered in our patient. However, the clinical improvement was 
gradually favourable, whereby we opted to maintain only corticosteroids. In severe cases, isoniazid or rifampicin have been proposed but 
this remains controversial, since they could lead to a decrease in the efficacy of iBCG on CisB[4]. 
ReA induced by iBCG is an exclusion diagnosis but should be considered in patients under this therapy. We add this case to the small number 
of previously described cases, increasing the number of alternative, though rarer, causes of ReA.
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